SARS-CoV-2疫苗过敏反应风险及推荐评估与管理:系统评价、Meta分析、GRADE评估与国际共识方法
该国际多学科专家共识通过系统评价与Meta分析,纳入26项研究(41,000,000剂接种),评估SARS-CoV-2疫苗过敏反应发生率、PEG及聚山梨酯过敏与过敏检测准确性。结果显示过敏反应发生率为每百万剂7.91例(95%CI 4.02-15.59;中等确定性),PEG皮肤试验敏感性差而特异性高(15项研究,极低确定性)。基于GRADE方法,推荐无严重过敏反应史者接种疫苗而非不接种或进行疫苗/辅料筛查过敏检测;有严重过敏反应史者建议与过敏专科医师共同决策。
要点
- SARS-CoV-2疫苗过敏反应发生率为每百万剂7.91例(95%CI 4.02-15.59;26项研究,中等确定性)。
- 对无SARS-CoV-2疫苗/辅料严重过敏反应史者,推荐接种疫苗而非不接种或进行疫苗/辅料筛查过敏检测。
- 对有SARS-CoV-2疫苗/辅料严重过敏反应史者,建议与过敏专科医师协商采用共同决策模式。
- PEG皮肤试验敏感性差、特异性高(15项研究,极低确定性)。
- 推荐进一步研究以明确SARS-CoV-2疫苗/疫苗辅料检测在可能对疫苗或辅料过敏者中的效用。
适用人群与场景
- 无SARS-CoV-2疫苗/辅料严重过敏反应史的个体。
- 有SARS-CoV-2疫苗/辅料严重过敏反应史的个体。
处置流程与药物剂量
- 对无SARS-CoV-2疫苗/辅料严重过敏反应史者,推荐接种疫苗而非不接种或进行SARS-CoV-2疫苗/辅料筛查过敏检测。
- 对有SARS-CoV-2疫苗/辅料严重过敏反应史者,建议与过敏专科医师协商采用共同决策模式。
研究设计与关键结果
- 系统评价与Meta分析,纳入26项研究,共41,000,000剂SARS-CoV-2疫苗接种,SARS-CoV-2疫苗过敏反应发生率为每百万剂7.91例(95%CI 4.02-15.59;中等确定性)。
- 过敏反应发生率为每百万患者年0.15例(95%CI 0.11-0.2)。
- PEG皮肤试验敏感性差、特异性高(15项研究,极低确定性)。
证据类型、等级与局限
- 证据类型:系统评价、Meta分析、GRADE评估及国际共识(改良Delphi小组)。
- 推荐基于GRADE方法制定,经改良Delphi小组同意。
- 过敏反应发生率证据确定性为中等;PEG皮肤试验准确性证据确定性为极低。
- 推荐进一步研究以明确SARS-CoV-2疫苗/疫苗辅料检测在可能对SARS-CoV-2疫苗或其辅料过敏者中的效用。
对床旁实践的改变
- 对无SARS-CoV-2疫苗/辅料严重过敏反应史者,推荐接种疫苗而非不接种或进行疫苗/辅料筛查过敏检测。
- 对有SARS-CoV-2疫苗/辅料严重过敏反应史者,建议与过敏专科医师协商采用共同决策模式。
- 作者推荐进一步研究以明确SARS-CoV-2疫苗/疫苗辅料检测在可能对SARS-CoV-2疫苗或其辅料过敏者中的效用。
指南或共识出处
- 国际多学科专家共识(J Allergy Clin Immunol Pract),基于系统评价、Meta分析、GRADE评估及改良Delphi小组。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Concerns for anaphylaxis may hamper severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunization efforts. We convened a multidisciplinary group of international experts in anaphylaxis composed of allergy, infectious disease, emergency medicine, and front-line clinicians to systematically develop recommendations regarding SARS-CoV-2 vaccine immediate allergic reactions. Medline, EMBASE, Web of Science, the World Health Organizstion (WHO) global coronavirus database, and the gray literature (inception, March 19, 2021) were systematically searched. Paired reviewers independently selected studies addressing anaphylaxis after SARS-CoV-2 vaccination, polyethylene glycol (PEG) and polysorbate allergy, and accuracy of allergy testing for SARS-CoV-2 vaccine allergy. Random effects models synthesized the data to inform recommendations based on the Grading of Recommendation, Assessment, Development, and Evaluation (GRADE) approach, agreed upon using a modified Delphi panel. The incidence of SARS-CoV-2 vaccine anaphylaxis is 7.91 cases per million (n = 41,000,000 vaccinations; 95% confidence interval [95% CI] 4.02-15.59; 26 studies, moderate certainty), the incidence of 0.15 cases per million patient-years (95% CI 0.11-0.2), and the sensitivity for PEG skin testing is poor, although specificity is high (15 studies, very low certainty). We recommend vaccination over either no vaccination or performing SARS-CoV-2 vaccine/excipient screening allergy testing for individuals without history of a severe allergic reaction to the SARS-CoV-2 vaccine/excipient, and a shared decision-making paradigm in consultation with an allergy specialist for individuals with a history of a severe allergic reaction to the SARS-CoV-2 vaccine/excipient. We recommend further research to clarify SARS-CoV-2 vaccine/vaccine excipient testing utility in individuals potentially allergic to SARS-CoV2 vaccines or their excipients.
参考来源
- Greenhawt M, Abrams EM, Shaker M, et al. The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach. J Allergy Clin Immunol Pract. 2021. PMID: 34153517. doi:10.1016/j.jaip.2021.06.006
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。